HK Stock Market Move | HANSOH PHARMA (03692) rose nearly 3% in the afternoon as HS-10582 tablets received the clinical trial approval notice issued by the NMPA.
Hansoh Pharmaceutical (03692) rose nearly 3% in the afternoon, and as of the time of writing, it was up 2.27%, trading at HKD 32.4, with a transaction volume of HKD 136 million.
HANSOH PHARMA (03692) rose nearly 3% in the afternoon, and as of the time of writing, it was up 2.27% at HKD 32.4, with a transaction volume of HKD 136 million.
In terms of news, HANSOH PHARMA announced that its self-developed Class 1 new drug HS-10582 tablets received the clinical trial approval notification from the National Medical Products Administration (NMPA) in China, intended for conducting clinical trials for "the treatment of adult primary hypercholesterolemia and mixed dyslipidemia."
Related Articles
CBHB (09668) adopts multiple measures to enhance the capacity and quality of the service industry.
HK Stock Market Move | MANULIFE-S (00945) rose nearly 3% after earnings, with core earnings in the second quarter increasing by 12% year-on-year. The company continues to advance its strategic priorities.
Orient: Ice wash exports maintain high prosperity, while domestic sales of white goods are expected to improve month-on-month.
CBHB (09668) adopts multiple measures to enhance the capacity and quality of the service industry.
HK Stock Market Move | MANULIFE-S (00945) rose nearly 3% after earnings, with core earnings in the second quarter increasing by 12% year-on-year. The company continues to advance its strategic priorities.
Orient: Ice wash exports maintain high prosperity, while domestic sales of white goods are expected to improve month-on-month.
RECOMMEND
